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Background and Aims: Cytokeratin-19 (CK-19) is a cancer stem cell marker expressed by a subpopulation of hepatocellular carcinomas (HCCs) associated with tumor aggressiveness. It has been shown that serum levels of CK-19 fragments (CYFRA 21-1) correlate with the HCC
expression of CK-19; hence we evaluated the prognostic value of serum CYFRA 21-1 compared to alpha-fetoprotein (AFP) and protein induced by vitamin-K absence-II (PIVKA-II) in patients with HCC.
Method: A total of 160 patients (28F/132M; age 65 [44–86] years) with a new diagnosis of HCC achieved between Nov-2012 and Jan-2018were retrospectively analyzed. All patients had cirrhosis and the main underlying etiology was viral (118/160, 73.8%). Barcelona Clinic Liver Cancer (BCLC) staging system was adopted for patients classification and therapies allocation (18 stage 0, 77 A, 39 B, 23 C, 3 D). Radiological response to treatment was assessed by modified
Response Evaluation Criteria in Solid Tumors (mRECIST). Serum samples were collected at HCC diagnosis; CYFRA 21-1, AFP and PIVKA-II were measured on LumipulseR G600 II (Fujirebio Inc, Japan).
Results: The median overall survival (OS) after HCC diagnosis was 35.1 (95%CI 27.1–35.1) months. At HCC diagnosis, median CYFRA 21–1, AFP and PIVKA-II levelswere 1.3 (95%CI 1.2–1.5) ng/mL,12.6 (95%CI 8.6–16.9) ng/mL and 199 (95%CI 146–316) mAU/mL, respectively.
CYFRA-21 showed a poor correlation with BCLC staging (rs = 0.157, p = 0.048) and PIVKA-II (rs = 0.163, p = 0.039) but no correlation with AFP (rs = 0.072, p = 0.368). At univariate analysis, CYFRA 21-1 >2.7 ng/mL resulted a significant factor for poor prognosis (Log-rank test, p <
0.001). Multivariate Cox regression showed that CYFRA 21-1 >2.7 ng/mL (HR = 3.45, 95%CI 1.84–6.46), AFP > 20 ng/mL (HR = 2.20, 95%CI 1.24–3.90), PIVKA-II >200 mAU/mL (HR = 2.38, 95%CI 1.29–4.39), BCLC stage (HR = 1.61, 95%CI 1.20–2.16) and radiological response
(HR = 0.21, 95%CI 0.08–0.55) were independent predictors of 3-year OS, while only CYFRA 21-1 >2.7 ng/mL (HR = 3.46, 95%CI 1.69–7.10), BCLC stage (HR = 2.00, 95%CI 1.36–2.95) and radiological response (HR = 0.09, 95%CI 0.01–0.72) were independent predictors of 1-year
OS.
Conclusion: Among investigated biomarkers, CYFRA 21-1 resulted the strongest independent predictor of OS. The determination of baseline serum CYFRA 21-1 may be a useful prognostic factor.

